Jared Whitlock
Reporter
Phone: 858-634-4636 Extension: 3130
Recent Stories
Turning Point Therapeutics Seeks $100 Million in IPO
Cancer drugmaker Turning Point Therapeutics recently filed paperwork calling for a $100 million initial public offering.
New CEO Appointed at Epic Sciences
Lloyd Sanders, previously with Myriad Genetics, has joined Epic Sciences as CEO.
Cellular Treatments for Diabetes Get $80M
BIOTECH: ViaCyte Built Up IP, Absorbed Rivals
In 1998, researchers derived stem cells from human embryos for the first time. With the advance came the hope of curing Type 1 diabetes.
San Diego Co. Sees Increasing Demand for CBD Products
CV Sciences is cashing in on rising demand for cannabidiol, or CBD.
PhaseBio Stock Jumps Following Good Results in Early-Stage Clinical Trials
PHARMA: Drug Used to Reverse Antiplatelet Activity
PhaseBio’s stock jumped March 18 after the company’s lead drug candidate showed promise in an early-stage clinical study.
Sharp HealthCare Wins Hearst Prize for Palliative Care Program
A Sharp HealthCare program that delivers palliative care at home captured the 2019 Hearst Prize.
CureMetrix’s Mammogram Software Wins FDA Approval
CureMetrix got the U.S. Food and Drug Administration’s blessing to market software that flags which mammograms raise suspicions of breast cancer.
PhaseBio Shares Rise on Clinical Study Data
PhaseBio’s stock jumped March 18 after the San Diego-based company’s lead drug candidate showed promise in an early-stage clinical study.
Life Sciences Leasing Activity Finished Strong in Q4 of 2018
For San Diego life sciences the fourth quarter of 2018 was the strongest of the year from a leasing perspective.
Potential Blockbuster Drug Could Bring Windfall to Scripps
Scripps Research stands to gain a royalty windfall from a drug candidate that slows brain atrophy in patients with multiple sclerosis.
